Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
Commentary

Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily

Pranay Nadella, MD, MPhil, Esperance Schaefer, MD, MPH and Clare Landefeld, MD, MS
Cleveland Clinic Journal of Medicine February 2026, 93 (2) 88-93; DOI: https://doi.org/10.3949/ccjm.93a.25045
Pranay Nadella
Division of General Internal Medicine and Primary Care, Brigham and Women’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: pnadella{at}mgb.org
Esperance Schaefer
Division of Gastroenterology, Hepatology, and Endoscopy, Brigham and Women’s Hospital, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Clare Landefeld
Department of Internal Medicine, Division of General Internal Medicine and Bioethics, University of California, Davis School of Medicine, Sacramento, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Figure 1
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1

    Proposed algorithm for liver disease screening in the primary care setting.

Tables

  • Figures
    • View popup
    TABLE 1

    Pharmacotherapy for alcohol use disorder

    MedicationEfficacyTypical dosageNotes
    NaltrexoneNumber needed to treat of 11 to prevent return to heavy drinking
    Number needed to treat of 18 to prevent return to any drinking
    Oral: 50–100 mg daily
    Subcutaneous: 380 mg monthly
    Generally first-line treatment given ease of dosing
    Contraindicated in concurrent opioid use or acute hepatitis
    Discuss risks and benefits in decompensated cirrhosis
    AcamprosateNumber needed to treat of 11 to prevent return to any drinkingaOral: 666 mg 3 times dailySafe in liver disease
    Contraindicated in severe kidney impairment
    DisulfiramLimited data suggest only effective when given under supervisionOral: 250–500 mg dailyContraindicated if any alcohol was used in preceding 12–48 hours
    Can cause severe reaction if alcohol is consumed up to 14 days after ingestion
    TopiramatebReduced percentage of drinking days and heavy drinking daysOral: maximum 100–150 mg twice dailyMore significant side-effect profile
    Requires slow dose escalation
    Use with caution in decompensated cirrhosis
    GabapentinbLimited data suggest may reduce drinking in patients with protracted withdrawal symptomsOral: up to 1,800 mg daily in 2 or 3 divided dosesMore significant side-effect profile
    Risk of misuse, especially with other substance use disorders
    BaclofenbVariable efficacy seen in trials, likely more effective in patients already abstinentOral: 10–25 mg 3 times dailySafe in hepatic impairment
    Glucagon-like peptide 1 agonists (eg, semaglutide)bEmerging evidence of reduced alcohol intakeSubcutaneous: weeklyMultiple ongoing trials evaluating benefit and safety
    Can target comorbid metabolic dysfunction–associated liver disease
    • ↵aBenefit only found in European trials where abstinent patients were recruited from treatment centers. Benefit not demonstrated in US trials with a more general population.

    • ↵bOff-label use.

    • Based on information from references 12–15.

    • View popup
    TABLE 2

    Alcohol Use Disorders Identification Test-Consumption

    QuestionScore
    0 points1 point2 points3 points4 points
    How often did you have a drink containing alcohol in the past year?NeverMonthly or less2–4 times per month2–3 times per week4 or more times per week
    How many drinks did you have on a typical day if you were drinking in the past year?1–23–45–67–910 or more
    How often did you have more than 6 drinks on 1 occasion in the past year?NeverLess than monthlyMonthlyWeeklyDaily or almost daily
    • A score of 3 or higher in women or 4 or higher in men is considered positive for heavy drinking.

    • Adapted from reference 23.

PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 93 (2)
Cleveland Clinic Journal of Medicine
Vol. 93, Issue 2
1 Feb 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily
Pranay Nadella, Esperance Schaefer, Clare Landefeld
Cleveland Clinic Journal of Medicine Feb 2026, 93 (2) 88-93; DOI: 10.3949/ccjm.93a.25045

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Preventing cirrhosis: Why primary care clinicians should screen for liver disease in patients who drink heavily
Pranay Nadella, Esperance Schaefer, Clare Landefeld
Cleveland Clinic Journal of Medicine Feb 2026, 93 (2) 88-93; DOI: 10.3949/ccjm.93a.25045
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • PREVALENCE OF ALCOHOL-RELATED LIVER DISEASE IS INCREASING
    • EVIDENCE SHOWS EARLY INTERVENTION CAN BENEFIT PATIENTS
    • A SIMPLE WAY TO INTEGRATE SCREENING INTO PRIMARY CARE
    • POSSIBLE IMPLEMENTATION CHALLENGES
    • OUR CLOSING ARGUMENT
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Suzetrigine: A novel nonopioid systemic analgesic
  • Vaccine hesitancy: Where are we heading?
Show more Commentary

Similar Articles

Subjects

  • Gastroenterology
  • Hepatology

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2026 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire